Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial
Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Amer M. Zeidan(Yale Cancer Center), Pierre Fenaux(Saint Louis University Hospital), David Valcárcel(Vall d'Hebron Hospital Universitari), Veronika Pozharskaya(Bristol-Myers Squibb (United States)), Thalia A. Farazi(Bristol-Myers Squibb (United States)), Matteo Della Porta(University of Milan), Jake Shortt(The University of Melbourne), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Yinzhi Lai(Bristol-Myers Squibb (United States)), Karen L. Keeperman(Bristol-Myers Squibb (United States)), Uwe Platzbecker(National Center for Tumor Diseases), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), Rami S. Komrokji(Moffitt Cancer Center), Barkha Aggarwal(Bristol-Myers Squibb (United States)), Tracy Krimmel(Bristol-Myers Squibb (United States))
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k